摘要
目的了解经高效抗逆转录病毒治疗(HAART)血友病合并丙型肝炎和艾滋病患者的临床疗效与不良反应。方法采用流式细胞仪定期检测CD4、CD3、CD8、自然杀伤细胞(NK)细胞计数;采用FDA推荐的病毒载量检测方法(bDNA)随访血浆病毒载量。结果43例患者在治疗3年后CD4+T淋巴细胞平均上升至257/mm3(P<0.001);HIVRNA平均降低至(2.26±1.10)log/ml(P<0.01)。结论HAART能有效抑制血友病合并丙型肝炎和艾滋病患者体内HIV的复制,有利于免疫功能重建。
Objective To observe the efficacy and safety profile of three-year treatment of HAART in 43 Hemophilia patients co-infected with HIV and HCV. Methods 43 hemophilia patients co-infected HIV and HCV were treated with HAART for 3 years. CD4, CD3, CD8 and NK cell counts of the patients were detected by FCM, and the viral load in the plasma was detected with FDA recommended bDNA method. Results The average CD4 count of the 43 patients increased to 257/ mms （P〈0. 001） and the average HIV RNA viral load descend to 2. 26±1.10 log/ml （P〈0. 0001）after treatment. Conclusions HAART regimen can efficiently inhibit HIV replication of the hemophilia patients who were co-infected with HIV and HCV. HAART can reconstruct the human immune sys tern of the patients with HIV and HCV coinfection.
出处
《中华传染病杂志》
CAS
CSCD
北大核心
2006年第1期35-38,共4页
Chinese Journal of Infectious Diseases
